A new study from Memorial Sloan Kettering Cancer Center highlights the promise of ulixertinib, a targeted therapy drug that blocks ERK, for treating certain forms of histiocytosis, including Erdheim-Chester Disease (ECD).
Led by Dr. Eli Diamond, a member of the ECDGA Ιατρική Συμβουλευτική Επιτροπή, this research marks an exciting step forward in the treatment of MAPK-driven histiocytic disorders. For many in our community, like Joey, a member of the ECDGA whose journey continues to inspire us, these scientific breakthroughs represent far more than clinical progress. They offer hope.
Read the νέα article from MSKCC:
https://www.mskcc.org/news/targeted-therapy-drug-ulixertinib-for-histiocytosis-blood
Access the full technical article in Cancer Cell:
https://www.sciencedirect.com/science/article/pii/S1535610825004064
At ECDGA, we are proud to support and share research that drives us closer to better care, more answers, and, someday, a cure.
Η Παγκόσμια Συμμαχία για τη Νόσο Erdheim-Chester (ECDGA) δεν παρέχει ιατρικές συμβουλές, διαγνώσεις ή θεραπείες. Όλο το περιεχόμενο παρέχεται αποκλειστικά για ενημερωτικούς σκοπούς. Για ιατρικά ζητήματα, παρακαλούμε να συμβουλευτείτε έναν επαγγελματία υγείας.